Sydnexis Announces Positive CHMP Opinion in Europe for SYD-101 for Slowing the
ProgressSanten is Sydnexis’ Licensing Partner to Commercialize SYD-101 within the EMEA Region upon issuance of a Marketing Authorization by the European Commission DEL MAR, Calif. – April 1, 2025 – Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has […]